HCWB HCWB
Company Profile ↓Company Overview
HCWB (HCWB) is a publicly traded company listed on with a market capitalization of $1.87M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Recent Developments
- Dec 2025 Revenue of $54.23K (-97.9% YoY); net profit $-7.96M.
- Trailing 12 Months Year-on-year growth — revenue -97.9%.
- 5-Year Trend Long-term compounding — revenue CAGR -57.9%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -57.90% |
| 1 Year: | -97.89% |
Stock Price Performance
| 1 Year: | -86.37% |
| 6 Months: | -48.50% |
| 3 Months: | +39.77% |
| 1 Month: | -23.27% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)41.42 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Revenue declined at -57.9% CAGR over 5 years.
- Trading 90.5% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 5.07K | 6.55K | 15.61K | 27.01K | 6.54M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.05K | 5.24K | 12.48K | 21.61K | 11.07K |
| Gross Profit | - | - | - | 0 | 0 | 0 | 1.79M | 166.80K | 361.81K | 12.53K | 120.41K | 174.78K | 614.75K | 180.41K | 85.28K | - | 1.01K | 1.31K | 3.12K | 5.40K | 6.53M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.69M | 3.36M | 3.28M | 2.95M | 3.28M |
| Operating Income | - | -2.78M | -2.71M | -3.41M | -2.75M | -4.09M | -1.88M | -3.51M | -4.02M | -5.36M | -4.51M | -5.08M | -7.49M | -15.14M | -3.68M | - | -1.69M | -3.36M | -3.28M | -2.95M | 3.25M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -1.25M | -1.30M | -4.24M | 1.10M | 4.07M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 528.88K | 330.96K | 142.57K | 226.54K | 123.69K |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -2.20M | -1.93M | -4.55M | 719.23K | 3.80M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | - | - | - | 330.19K |
| Net Income | -2.38M | -2.78M | -2.71M | -2.84M | -2.75M | -4.09M | -2.06M | -3.51M | -3.91M | -5.07M | -4.30M | -4.94M | -7.47M | -15.28M | -3.90M | - | -2.20M | -1.93M | -4.55M | 719.23K | 3.47M |
| Diluted EPS | - | - | - | - | -0.66 | -0.14 | -0.06 | -0.10 | -0.11 | -0.14 | -0.12 | -0.14 | -0.20 | -16.16 | -4.13 | - | -11.82 | -5.39 | -12.12 | -6.12 | 2.22 |
| R&D Expense | - | 2.07M | 2.10M | 2.33M | 1.67M | 2.69M | 1.79M | 1.97M | 2.65M | 2.26M | 1.62M | 1.67M | 2.12M | 2.03M | 1.19M | - | 1.48M | 1.23M | 1.40M | - | 1.26M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | 4.10M | 0 | 6.72M | 2.84M | 2.57M | 54.23K |
| Gross Profit | - | 0 | 2.59M | 560.36K | 959.40K | 10.85K |
| Operating Income | -5.82M | -13.37M | -15.08M | -25.72M | -29.46M | -13.16M |
| Net Income | -5.80M | -12.86M | -14.90M | -24.99M | -30.02M | -7.96M |
| Diluted EPS | - | -0.69 | -0.42 | -0.70 | -30.96 | -10.63 |
| R&D Expense | 7.26M | 8.17M | 9.34M | 7.68M | 6.39M | 5.44M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 15.40M | - | 46.81M | 28.51M | 30.24M | 24.52M |
| Current Assets | - | - | - | 34.07M | 6.40M | 5.70M | 2.28M |
| Cash & Equivalents | 7.36M | 8.46M | - | 22.33M | 3.60M | 4.67M | 1.95M |
| Inventory | - | - | - | - | - | - | - |
| Receivables | - | - | - | 417.69K | 1.54M | 582.20K | 32.17K |
| Total Liabilities | - | - | - | 9.38M | 15.05M | 37.01M | 21.76M |
| Current Liabilities | - | 1.00M | - | 2.96M | 8.75M | 29.63M | 21.06M |
| Long Term Debt | - | - | - | 6.41M | 6.30M | 7.38M | - |
| Total Debt | - | - | - | 6.41M | 6.30M | 13.69M | 6.81M |
| Total Equity | -9.68M | -16.72M | - | 37.43M | 13.46M | -6.77M | 2.76M |
| Shares Outstanding | - | - | - | 149.49K | 150.10K | 185.59K | 546.63K |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -10.43M | -10.98M | -10.39M | -22.51M | -14.23M | -13.39M |
| Investing Cash Flow | -186.68K | -35.02M | 14.71M | 3.80M | -261.62K | 0 |
| Financing Cash Flow | 11.72M | 49.27M | 6.27M | -14.53K | 15.57M | 10.67M |
| Capital Expenditure | -186.68K | -47.26K | -10.28M | -6.20M | -261.62K | -0 |
| Free Cash Flow | -10.62M | -11.02M | -20.66M | -28.72M | -14.49M | -13.39M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | 38.5% | 19.7% | 37.4% | 20.0% |
| Operating Margin % | -142.1% | - | -224.3% | -905.0% | -1,147.6% | -24,270.7% |
| Net Margin % | -141.5% | - | -221.7% | -879.5% | -1,169.7% | -14,677.1% |
| ROE % | 34.7% | - | -39.8% | -185.7% | 443.5% | -287.9% |
| ROCE % | -40.5% | - | -34.4% | -130.1% | -4,847.3% | -380.7% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for HCWB
HCW Biologics (HCWB) director buys stock, entitled to new warrants - Stock Titan
<a href="https://news.google.com/rss/articles/CBMisAFBVV95cUxQLWw2c3FRSGcxcl9XeURMQUxRbl9CYmdZaVY2MUZoZXVZR2EyR1VRZ2VzbXduTk9vTWRQbkdHampBbmduUjBSV0FPd1hWdElGUS1MX2doTEV4NTlzcDh3dHJ5MUV1NFRLSXdJRnFfUXFPbS1qa3N0SFFXSjcwNE5BUEtXeGtpWDZyMF9UZV…
Price to sales forward of HCW Biologics Inc. – NASDAQ:HCWB - TradingView
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxPc3pQUmN1UnEyYWczT0MycU1rN1k3OGdfTHlTZWdzcFNScjU1dzZockVVTXJObHlJbmo2Tk9WY0d0bnFSMjRPbXpEQkN1eDNPUHpaYW1OcmFHakNQRU5ZdklRLVhnb1l2VjdSa1FFdjMtcjBYWUpIUVZpRU9NWTZFS0FKaFk0UGJzT3Y5ZX…
HCWB Insider Buying: CEO and 10% Owner Hing Wong Purchases 23,21 - GuruFocus
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxNM1FTWV9BX3Q3VEt4YndPTlBqR1FaajAtWU04bFdDbWEyYTVxejFDNlVSUFJ5MGxJcGdlSjVYQkZqTERWMmpEemQxWFA1NlNGVVl1cTVERnlGbVlFY3BBNjBUQ0FBa0I1bFNrLV9WODZjT29JSWd1Y2FvZ1RKcGNNcDd6SEUtUXgxQUpXam…
HCW Biologics Inc Stock Short Interest Rises to 58.43% - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMikwFBVV95cUxOQnRKeGtPaG1HbkhzYnhxeW0wcFU2cmtIaHBOTUM1Yy1EOGZqNVhXdjg1a19HSHR6MHVFQ1lacGtsaUdnTzAyWGw4VENSRElLMVd3YUd5aXZQNWJMcHNTUXJsM0tGY3BHVHhJeU1MV254aFdHLTB6dXk5NVVrcXNDTThqSTJORUdFdjJsOD…
HCWB Stock Soars As Q1 Profit And Pipeline Fuel Momentum - StocksToTrade
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE43UjFBUHduTTNRS2Nmb1NRZDVhZDh4WjJoOHRFNTVFeXc3VkV0OW9xaFg5NXdVY0RKVHJDY1FPYWdubXFSbzI0d25tRVd1enc2dFNfMHVpRlF5Zm1Hc3F3VS0wWXlzUlBtMkpyODMtZ0Q4TXZOSDFpeDVB?oc=5" target="_blank">HCW…
Why HCW Biologics Stock Is Surging On Thursday? - Benzinga
<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxPeGM0VHVmLWpXbjdldENZVFNPNUNBbWtpVVVKRXJkWGNnVkZ1Q21fNmxnV2Fael9RMnJKY3BEWWx3a0lFWElnQ2Vwd1dWVk9CYkpBakxIY1kxNVFIZUhaZl9OMzlaS3kwWEJSVU0xWEw5UGdFMm9RemZQazJzSEcyYVJ5T2I5bXpXQnptSl…
HCWB — Frequently Asked Questions
What is the current share price of HCWB?
As of 2026-08-05 17:25 PDT, HCWB trades at $3.43 on NASDAQ/NYSE. Its 52-week range is $1.61 to $36.12.
What is the market capitalisation of HCWB?
HCWB has a market capitalisation of $1.87M on NASDAQ/NYSE.
What is the P/E ratio of HCWB?
HCWB trades at a trailing price-to-earnings (P/E) ratio of -0.32. Its price-to-book (P/B) ratio is 0.68.
Is HCWB a good stock to buy?
This page provides a data-driven analysis of HCWB, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.